E-cigarettes may be more effective in helping pregnant smokers quit

May.17.2022
E-cigarettes may be more effective in helping pregnant smokers quit
Pregnant smokers using e-cigarettes are more likely to quit smoking compared to nicotine patch users, according to a study.

Research shows that pregnant smokers are more likely to quit smoking using electronic cigarettes after four weeks than nicotine patches.

 

Researchers have discovered that electronic cigarettes may be equally safe for pregnant women trying to quit smoking as nicotine patches, and may even be a more effective tool.

 

Smoking during pregnancy increases the risk of adverse outcomes such as preterm birth, miscarriage, and low birth weight. However, quitting this habit can be a challenging process.

 

Dr. Francesca Pesola from Queen Mary University of London, the author of this new study, stated that "many pregnant smokers find it difficult to quit smoking using current cessation aids (including nicotine patches) and continue smoking throughout their pregnancy.

 

Although it has been discovered that electronic cigarettes are more effective than nicotine patches in helping people quit smoking, Pesola points out that despite the increasing use of electronic cigarettes by pregnant women, research on their effectiveness or safety is scarce.

 

After attempting to quit smoking for four weeks, 15.4% of individuals who reported using e-cigarettes said that they no longer smoke, compared to only 8.6% of those using nicotine patches.

 

Smoking during pregnancy increases the risk of negative outcomes, including premature birth, miscarriage, and low birth weight for the infant. However, quitting this habit can be a challenging process.

 

Although electronic cigarettes have been shown to be more effective than nicotine patches in helping people quit smoking, Pesola points out that despite an increase in the use of e-cigarettes among pregnant women, there is little research on their effectiveness or safety.

 

Researchers led by Pesola reported in the journal Nature Medicine that they randomly assigned 569 pregnant smokers to use e-cigarettes and 571 pregnant women to use nicotine patches – a nicotine replacement therapy that can already be prescribed during pregnancy. The participants were an average of 15.7 weeks pregnant and smoked 10 cigarettes per day.

 

Only 40% of participants received an electronic cigarette and 23% received a patch, both of which were used for at least four weeks. However, during the study period, those who received electronic cigarettes had higher usage rates and longer usage times.

 

Excluding participants who self-reported not smoking but using nicotine products other than those assigned to them, such as those using nicotine patches along with e-cigarettes, the research team found that those who received e-cigarettes appeared to do better in terms of smoking cessation.

 

After attempting to quit smoking for four weeks, 15.4% of individuals self-reported that they had not smoked, compared to only 8.6% of those who were given patches. At the end of their pregnancies, 19.8% of the e-cigarette group self-reported that they had quit smoking, while only 9.7% of the patch group had done so.

 

Only a small number of participants provided saliva samples to confirm smoking cessation at the end of pregnancy, but once those who used unassigned products were excluded, the research group found that the quit rates among the electronic cigarette group were higher.

 

Additionally, the research team found that the incidence of adverse events was similar between individuals who were given cigarettes and those who were given patches. More importantly, although the average birth weight of infants was similar, low birth weight was more common in the patch group.

 

However, this study has limitations, including low compliance and the use of electronic cigarettes that differ from modern devices.

 

The author further stated that due to the potential risks of nicotine during pregnancy, it is best for pregnant women to quit smoking without using nicotine-containing products.

 

Pesola stated, "We only recommend nicotine use for smokers who wish to quit traditional cigarettes.

 

However, she added, "The risks posed to mothers or infants by using electronic cigarettes are no greater than those posed by nicotine patches. Both are better choices than continuing to smoke throughout the entire course of pregnancy.

 

Source: The Guardian

 

E-cigarettes are equally safe as nicotine patches for pregnant women who smoke and are attempting to quit, according to a report in The Guardian on May 16, 2022.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Asia Manufacturing Corp. has invested ₱2.1 billion, or about $37 million, in its manufacturing site in Malvar, Batangas, Philippines, to expand tobacco-processing capabilities. About ₱1.9 billion is allocated to JTI's first Dry Ice Expanded Tobacco, or DIET, facility in Southeast Asia, while more than ₱177 million has been spent on expanding its Controlled Atmosphere treatment facility. The Batangas plant supplies the Philippine market and exports to 22 overseas markets, making it one of JTI's key manufacturing hubs in Asia.
Sep.24
Malaysia’s Vape Rules Face Review as Health Minister Dzulkefly Ahmad Addresses Dropped Nicotine Appeal
Malaysia’s Vape Rules Face Review as Health Minister Dzulkefly Ahmad Addresses Dropped Nicotine Appeal
According to Free Malaysia Today on August 26, 2026, Malaysia’s Health Minister Dzulkefly Ahmad said the Health Ministry would explain the government’s decision to withdraw its appeal against a High Court ruling involving the exemption of liquid nicotine used in vape products from the Poisons List. The High Court previously ruled that the exemption decision was irrational. Dzulkefly said withdrawing the appeal did not mean the government would stop regulating vaping, and that future regulatory approaches would continue under existing legal frameworks.
Aug.28
Product | JT Expands Vote-Winning EVO Cacao Mint Crystal to Nationwide Retail in Japan, Adds 22-Stick Limited Pack at Same Price
Product | JT Expands Vote-Winning EVO Cacao Mint Crystal to Nationwide Retail in Japan, Adds 22-Stick Limited Pack at Same Price
Japan Tobacco (JT) will expand EVO Cacao Mint Crystal from limited channels to nationwide retail in Japan from October 6, 2026. The Ploom tobacco stick ranked first in the brand's first consumer voting campaign for new tobacco-stick SKUs held earlier this year. JT will also introduce a limited 22-stick pack at the same JPY 620 price as the standard 20-stick pack. The capsule-format product combines menthol with sweet, bittersweet cacao notes and adds a berry nuance when the capsule is crushed.
Sep.09
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
Product | PMI Japan Expands ZYN by IQOS Strength Portfolio With Strong Series, Increasing Lineup to 12 Products
Product | PMI Japan Expands ZYN by IQOS Strength Portfolio With Strong Series, Increasing Lineup to 12 Products
Philip Morris Japan (PMJ) has expanded the ZYN by IQOS oral tobacco pouch portfolio in Japan with four new ZYN Strong products, adding a third intensity level alongside the existing Low and Medium ranges. The Strong series first entered selected duty-free channels in Japan on July 1, 2026, before expanding to IQOS stores, the ZYN Online Store and selected tobacco retailers from August 18. The expansion increases the Japanese ZYN by IQOS lineup from eight to 12 products.
Aug.20